Genetics of neurological disorders

References

• Campion D, Dumanchin C, Hannequin D et al. Early-onset autosomal dominant Alzheimer's disease: prevalence, genetic heterogeneity and mutation spectrum. Am. J Hum. Genet. 65,664–670 (1999).
   PubMed Web of Science ®Google Scholar
• Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl. J Med. 348,1356–1364 (2003).
   PubMed Web of Science ®Google Scholar
• ••Describes the molecular pathways, genemutations and pathology of Parkinson's (PD) and Alzheimer's disease (AD).
   Google Scholar
• Farrer LA, Cupples LA, Haines JL et al. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease. A meta-analysis. APOE and Alzheimer's disease Meta Analysis Consortium. JAMA 278,1349–1356 (1997).
   Google Scholar
• Roks G. Alzheimer's disease. Present and future role of genetics. Tfidschr Gerontol. Geriab: 34,13-20 (2003).
   Google Scholar
• Murrell JR, Hake AM, Quaid KA, Farlow MR, Ghetti B. Early-onset Alzheimer's disease caused by a new mutation (V717L) in the amyloid precursor protein gene. Arch. Neurol. 57,885-887 (2000).
   Google Scholar
• De Jonghe C, Esselens C, Kumar-Singh S et al. Pathogenic APP mutations near the y-secretase cleavage site differentially affect Al3 secretion and APP C-terminal fragment stability. Hum. MoL Genet. 10,1665-1671 (2001).
   Google Scholar
• Nunan J, Small DH. Proteolytic processing of the amyloid-0 protein precursor of Alzheimer's disease. Essays Biochem. 38, 37–49 (2002).
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A042(43) and A040 in senile plaques with end-specific Al3 monoclonals: evidence that an initially deposited species is A042(43). Neuron 13, 45–53 (1994).
   PubMed Web of Science ®Google Scholar
• Steiner H, Haass C. Intramembrane proteolysis by presenilins. Nature Rev MoL Cell. Biol. 1, 217–224 (2000).
   PubMed Web of Science ®Google Scholar
• Hutton M, Perez-Tur J, Hardy J. Genetics of Alzheimer's disease. Essays Biochem. 33,117–131 (1998).
   PubMedGoogle Scholar
• Martin JB. Molecular basis of the neurodegenerative disorders. N Engl. J. Med. 340,1970–1980 (1999).
   PubMedGoogle Scholar
• ••Describes schematically the molecularmechanism of the pathogenesis of AD.
   Google Scholar
• Saito T, Takaki Y, Iwata N, Trojanowski J, Saida TC. Alzheimer's disease, neuropeptides, neuropeptidase and amyloid-0 peptide metabolism. Sci. Aging Knowledge Environ. 2003(3), PE 1 (2003).
   Google Scholar
• Schupf N, Sergievsky GH. Genetic and host factors for dementia in Down's syndrome. Br. J. Psychiatry180, 405–410 (2002).
   PubMedGoogle Scholar
• Peacock ML, Murman DL, Sima AA, Warren JT Jr, Roses AD, Fink JK. Novel amyloid precursor protein gene mutation (codon 665Asp) in a patient with late-onset Alzheimer's disease. Ann. Neurol. 35,432-438 (1994).
   Google Scholar
• Miklossy J, Taddei K, Suva D et al. Two novel presenilin-1 mutations (Y2565 and Q222H) are associated with early-onset Alzheimer's disease. Neurobiol. Aging 24,655–662 (2003).
   Google Scholar
• Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and y-secretase activity. Nature 398,513–517 (1999).
   PubMed Web of Science ®Google Scholar
• Scheuner D, Eckman C, Jensen M etal. Secreted amyloid 0-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 2, 864–870 (1996).
   Google Scholar
• Takao M, Ghetti B, Hayakawa I et al. A novel mutation (G217D) in thepresenilin 1 gene (FSEN1) in a Japanese family: presenile dementia and Parkinsonism are associated with cotton wool plaques in the cortex and striatum. Acta NeuropathoL 104,155–170 (2001).
   Google Scholar
• Theuns J, Del Favero J, Dermaut B et aL Genetic variability in the regulatory region of presenilin 1 associated with risk for Alzheimer's disease and variable expression. Hum. MoL Genet. 9,325-331 (2000).
   Google Scholar
• Matsubara-Tsutsui M, Yamagata H, Morishima A et aL The 4,752 C/T polymorphism in the presenilin 1 gene increases the risk of Alzheimer's disease in apolipoprotein E4 carriers. Intern. Med. 41, 823–828 (2002).
   Google Scholar
• Colacicco AM, Panza F, Basile AM et aL F175S change and a novel polymorphism in presenilin-1 gene in late-onset familial Alzheimer's disease. Eur. NeuroL 47, 209–213 (2002).
   Google Scholar
• Katayama T, Manabe T, Tohyama M. Recent progress in HMGA la which causes aberrant splicing of presenilin-2 pre-mRNA in sporadic Alzheimer's disease. Nippon Rinsho 61,677–688 (2003).
   Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297,353–356 (2002).
   PubMed Web of Science ®Google Scholar
• •Describes the pathological pathways in AD.
   Google Scholar
• Seshadri S, Drachman DA, Lippa CF. Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know and what they should know. Arch. NeuroL 52,1074–1079 (1995).
   Google Scholar
• •Explains epidemiology of AD in detail.
   Google Scholar
• Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Ann. Rev NeuroscL 19,53-77 (1996).26 Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Ann. Rev PharmacoL ToxicoL 43,545–584 (2003).
   Google Scholar
• •Describes in detail the pathology of AD.
   Google Scholar
• Gomez-Ramos P, Mufson EJ, Moran MA. Apolipoprotein E irnmunoreactivity in neurons and neurofibrillary degeneration of aged non-demented and Alzheimer's disease patients. Microsc. Res. Tech. 55,48–58 (2001).
   Google Scholar
• Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve and treatment opportunities. Neurology51, S2—S17 (1998).
   Google Scholar
• Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology55,533–538 (2000).
   PubMed Web of Science ®Google Scholar
• Blacker D, Wilcox MA, Laird NM et al. a-2 macroglobulin is genetically associated with Alzheimer's disease. Nature Genet. 19, 357–360 (1998).
   PubMed Web of Science ®Google Scholar
• Luedecking-Zimmer E, DeKosky ST, Chen Q, Barmada MM, Kamboh MI. Investigation of oxidized LDL-receptor 1 (OLR1) as the candidate gene for Alzheimer's disease on chromosome 12. Hum. Genet. 111,443-451 (2002).
   Google Scholar
• Crawford FC, Freeman MJ, Schinka JA et al. A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology55, 763–768 (2000).
   PubMed Web of Science ®Google Scholar
• Beyer K, Lao JI, Latorre P et al. Methionine synthase polymorphism is a risk factor for Alzheimer's disease. Neuroreport 14, 1391–1394 (2003).
   PubMedGoogle Scholar
• Urakami K, Wakutani Y, Wada-Isoe K, Yamagata K, Adachi Y, Nakashima K. Analysis of causative genes and genetic risk factor in Alzheimer's disease. Nippon Ronen Igakkai Zasshi 38,769–771 (2001).
   Google Scholar
• Kunugi H, Ueki A, Otsuka M et al. A novel polymorphism of the brain-derived neurotrophic factor (BDNF) gene associated with late-onset Alzheimer's disease. MoL Psychiatry6,83–86 (2001).
   PubMed Web of Science ®Google Scholar
• Kawamata J, Shimohama S. Association of novel and established polymorphisms in neuronal nicotinic acetylcholine receptors with sporadic Alzheimer's disease. J Alzheimer s Dis. 4,71–76 (2002).
   PubMedGoogle Scholar
• Bertram L, Tanzi RE. Of replications and refutations: the status of Alzheimer's disease genetic research. CUIT: NeuroL Neurosci. Rep. 1,442–450 (2001).
   Google Scholar
• ••Extensive and complete review on AD.
   Google Scholar
• Prince JA, Feuk L, Gu HF et al. Genetic variation in a haplotype block spanning IDE influences Alzheimer's disease. Hum. Mutat 22,363–371 (2003).
   PubMed Web of Science ®Google Scholar
• Matsubara M, Yamagata H, Kamino K et al. Genetic association between Alzheimer's disease and the a-synuclein gene. Dement. Geriatr. Cogn. Disord. 12, 106–109 (2001).
   PubMed Web of Science ®Google Scholar
• Grasbon-Frodl EM, Kosel S, Sprinzl M, von Eitzen U, Mehraein P, Graeber MB. Two novel point mutations of mitochondrial tRNA genes in histologically confirmed Parkinson's disease. Neurogenetics 2,121–127 (1999).
   Google Scholar
• Lukiw WJ, Bazan NG. Neuroinflammatory signaling upregulation in Alzheimer's disease. Neurochem. Res. 25,1173–1184 (2000).
   PubMed Web of Science ®Google Scholar
• Bagli M, Papassotiropoulos A, Knapp M etal. Association between an interleukin-6 promoter and 3' flanking region haplotype and reduced Alzheimer's disease risk in a German population. Neurosci. Lett. 283, 109–112 (2000).
   Google Scholar
• Saunders AM, Hulette 0, Welsh-Bohmer KA etal. Specificity, sensitivity and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet 348,90–93 (1996).
   Google Scholar
• Yan Q, Zhang J, Liu H etal. Anti-inflammatory drug therapy alters (3-amyloid processing and deposition in an animal model of Alzheimer's disease. Neurosci. 23,7504-7509 (2003).
   Google Scholar
• Chapman PF, Falinska AM, Knevett SG, Ramsay ME Genes, models and Alzheimer's disease. Trends Genet. 17, 254–261 (2001).
   PubMed Web of Science ®Google Scholar
• •Describes various mutations within genes and corresponding proteins and the implication of these changes in the pathogenesis of AD.
   Google Scholar
• Morgan D. Antibody therapy for Alzheimer's disease. Expert Rev Vaccines 2, 53–59 (2003).
   PubMedGoogle Scholar
• Birmingham K, Frantz S. Set back to Alzheimer vaccine studies. Nature Med. 8, 199–200 (2002).
   PubMed Web of Science ®Google Scholar
• Schenk D, Seubert P, Ciccarelli RB. Immunotherapy with (3-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol. 20,679-681 (2001).
   Google Scholar
• Morgan D, Diamond DM, Gottschall PE etal. A 13 peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408,982–985 (2000).
   Google Scholar
• Schenk D, Barbour R, Dunn W etal. Immunization with arnyloid-13 attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400,173–177 (1999).
   Google Scholar
• Lynch T, Sano M, Marder KS etal. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology44,1878–1884 (1994).
   Google Scholar
• Yancopoulou D, Crowther RA, Chakrabarti L, Gydesen S, Brown JM, Spillantini MG. Tau protein in frontotemporal dementia linked to chromosome 3 (FTD-3). I NeuropathoL Exp. NeuroL 62,878–882 (2003).
   Google Scholar
• Katsuragi S, Teraoka K, Ikegami K et aL Late onset X-linked hydrocephalus with normal cerebrospinal fluid pressure. Psychiatry Clin. Neurosci. 54,487–492 (2000).
   PubMedGoogle Scholar
• Arai H, Higuchi S, Muramatsu T, Iwatsubo T, Sasaki H, Trojanowski JQ. Apolipoprotein E gene in diffuse Lewy body disease with or without coexisting Alzheimer's disease. Lancet344,1307 (1994).
   PubMedGoogle Scholar
• Nacmias B, Tedde A, Guarnieri BM etal. Analysis of apolipoprotein E, al-antichymotrypsin and presenilin-1 genes polymorphisms in dementia caused by normal pressure hydrocephalus in man. Neurosci. Lett. 229,177-180 (1997).
   Google Scholar
• Sveinbjornsdottir S, Hicks AA, Jonsson T et aL Familial aggregation of Parkinson's disease in Iceland. N EngL J Med. 343, 1765–1770 (2000).
   PubMed Web of Science ®Google Scholar
• Tanner CM, Ottman R, Goldman SM et al. Parkinson's disease in twins: an etiologic study. JAMA 281,341–346 (1999).
   PubMed Web of Science ®Google Scholar
• •Explains the penetrance and epidemiology of genetic forms of PD.
   Google Scholar
• Farrer M, Gwinn-Hardy K, Hutton M, Hardy J. The genetics of disorders with synuclein pathology and Parkinsonism. Hum. MoL Genet. 8,1901–1905 (1999).
   PubMedGoogle Scholar
• Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. a-Synuclein in Lewy bodies. Nature 388, 839–840 (1997).
   PubMed Web of Science ®Google Scholar
• •Observations and descriptions of pathogenesis and molecular mechanisms leading to PD.
   Google Scholar
• Kruger R, Kuhn W, Muller T et aL Ala30Pro mutation in the gene encoding a-synuclein in Parkinson's disease. Nature Genet. 18,106–108 (1998).
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Higgins JJ, Golbe LI et aL Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274,1197–1199 (1996).
   PubMed Web of Science ®Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E et aL Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science 276,2045–2047 (1997).
   PubMed Web of Science ®Google Scholar
• Tu PH, Galvin JE, Baba M et aL Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble a-synuclein. Ann. NeuroL 44,415–422 (1998).
   PubMed Web of Science ®Google Scholar
• Tan EK, Tan C, Shen H et al. a-synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability. Neurosci. Lett. 336,70–72 (2003).
   PubMed Web of Science ®Google Scholar
• Singleton AB, Farrer M, Johnson J et aL a-synuclein locus triplication causes Parkinson's disease. Science 302,841 (2003).
   PubMed Web of Science ®Google Scholar
• Goldberg MS, Fleming SM, Palacino JJ et aL Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278, 43628–43635 (2003).
   PubMed Web of Science ®Google Scholar
• Masliah E, Rockenstein E, Veinbergs I et al. Dopaminergic loss and inclusion body formation in a-synuclein mice: implications for neurodegenerative disorders. Science 287,1265–1269 (2000).
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Vila M, Lincoln S et al. Lack of nigral pathology in transgenic mice expressing human a-synuclein driven by the tyrosine hydroxylase promoter. NeurobioL Dis. 8,535–539 (2001).
   PubMed Web of Science ®Google Scholar
• Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck U. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl Acad. Sci. USA 100, 4078–4083 (2003).
   PubMed Web of Science ®Google Scholar
• Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 404, 394–398 (2000).
   PubMed Web of Science ®Google Scholar
• •Describes animal models for the study of complex neurodegenerative diseases.
   Google Scholar
• Lakso M, Vartiainen S, Moilanen AM et al. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human a-synuclein. Neurochem. 86,165–172 (2003).
   PubMed Web of Science ®Google Scholar
• Shulman JM, Shulman LM, Weiner WJ, Feany MB. From fruit fly to bedside: translating lessons from Drosophila models of neurodegenerative disease. CUIT: Opin. NeuroL 16,443–449 (2003).
   Google Scholar
• Dou F, Netzer WJ, Tanemura K et al. Chaperones increase association of tau protein with microtubules. Proc. Natl Acad. Sci. USA 100,721–726 (2003).
   PubMed Web of Science ®Google Scholar
• McLean PJ, Kawamata H, Shariff S et al. Torsin A and heat shock proteins act as molecular chaperones: suppression of a-synuclein aggregation. J. Neurochem. 83, 846–854 (2002).
   PubMed Web of Science ®Google Scholar
• Bonini NM. Chaperoning brain degeneration. Proc. Natl Acad. Sci. USA 99\(Suppl. 4), 16407–16411 (2002).
   Google Scholar
• Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of a-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295,865–868 (2002).
   Google Scholar
• Kitada T, Asakawa S, Hattori N et al. Mutations in the parkin gene cause autosomal recessive juvenile Parkinsonism. Nature 392,605–608 (1998).
   PubMed Web of Science ®Google Scholar
• Matsumine H, Saito M, Shimoda-Matsubayashi S et al. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am. J Hum. Genet. 60,588-596 (1997).
   Google Scholar
• Hilker R, Klein C, Ghaemi M et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial Parkinsonism associated with mutations in the parkin gene. Ann. NeuroL 49,367–376 (2001).
   PubMed Web of Science ®Google Scholar
• Farrer M, Chan P, Chen R et aL Lewy bodies and Parkinsonism in families with parkin mutations. Ann. NeuroL 50, 293–300 (2001).
   PubMed Web of Science ®Google Scholar
• Cookson MR. Parkin's substrates and the pathways leading to neuronal damage. Neuromolecular Med. 3,1–13 (2003).
   PubMedGoogle Scholar
• •Involvement of specific proteins in neurodegeneration, which occurs during progressive PD.
   Google Scholar
• Leroy E, Boyer R, Auburger G et al. The ubiquitin pathway in Parkinson's disease. Nature 395,451–452 (1998).
   PubMed Web of Science ®Google Scholar
• •Describes mutant proteins, their mechanism and implications in metabolic pathways leading to PD.
   Google Scholar
• Shimura H, Schlossmacher MG, Hattori N et al. Ubiquitination of a new form of a-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293,263-269 poly
   Google Scholar
• Klein C. The genetics of Parkinson syndrome. Schweiz. Rundsch. Med. Prax. 90,1015–1023 (2001).
   Google Scholar
• ••A comprehensive review of PD.
   Google Scholar
• Wintermeyer P, Kruger R, Kuhn W et al. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreportll, 2079-2082 (2000).
   Google Scholar
• El Agnaf OM, Jakes R, Curran MD, Wallace A. Effects of the mutations A1a30 to Pro and Ala53 to Thr on the physical and morphological properties of a-synuclein protein implicated in Parkinson's disease. FEBS Lett. 440,67–70 (1998).
   PubMedGoogle Scholar
• Lennox G, Lowe J, Morrell K, Landon M, Mayer RJ. Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. NeuroL Neurosurg. Psychiatry52,67–71 (1989).
   Google Scholar
• Shimura H, Hattori N, Kubo S et al. Familial Parkinson's disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genet. 25,302–305 (2000).
   PubMed Web of Science ®Google Scholar
• •Describes pathological processes leading to PD.
   Google Scholar
• Van Duijn CM, Dekker MC, Bonifati V et al. Park7, a novel locus for autosomal recessive early-onset Parkinsonism, on chromosome 1p36. Am. J Hum. Genet. 69, 629–634 (2001).
   Google Scholar
• Bonifati V, Rizzu P, van Baren MJ et al Mutations in the DJ-1 gene associated with autosomal recessive early-onset Parkinsonism. Science 299,256–259 (2003).
   PubMed Web of Science ®Google Scholar
• Farrer M, Gwinn-Hardy K, Muenter M etal. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum. Md. Genet. 8,81-85 (1999).
   Google Scholar
• Gasser T, Muller-Myhsok B, Wszolek ZK et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nature Genet. 18,262–265 (1998).
   PubMed Web of Science ®Google Scholar
• Valente EM, Bentivoglio AR, Dixon PH et al. Localization of a novel locus for autosomal recessive early-onset Parkinsonism, PARK6, on human chromosome 1p35-p36. Am. j Hum. Genet. 68,895-900 (2001).
   Google Scholar
• Hardy J, Cookson MR, Singleton A. Genes and Parkinsonism. Lancet Neurol 2, 221–228 (2003).
   PubMed Web of Science ®Google Scholar
• Hicks AA, Petursson H, Jonsson T et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann. Neurol 52,549–555 (2002).
   PubMed Web of Science ®Google Scholar
• Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata E A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol 51,296–301 (2002).
   Google Scholar
• Zimprich A, Muller-Myhsok B, Farrer M et al. The PARK8 locus in autosomal dominant Parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am. I Hum. Genet. 74,11-19 (2004).
   Google Scholar
• Le WD, Xu P, Jankovic J et al. Mutations in NR4A2 associated with familial Parkinson's disease. Nature Genet. 33,85–89 (2003).
   PubMed Web of Science ®Google Scholar
• Clayton DF, George JM. Synucleins in synaptic plasticity and neurodegenerative disorders. j Neurosci. Res. 58,120-129 (1999). too Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both a-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97,571–576 (2000).
   Google Scholar
• Hardy J. Pathways to primary neurodegenerative disease. Neurologia 17, 399–401 (2002).
   PubMedGoogle Scholar
• ••Extensive review of genes implicated in PD.
   Google Scholar
• Chung KK, Zhang Y, Lim KL et al. Parkin ubiquitinates the a-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson's disease. Natum Med. 7,1144–1150 (2001).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Engelender S, Igarashi S et al. Inducible expression of mutant a-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Ma. Genet. 10,919–926 (2001).
   PubMed Web of Science ®Google Scholar
• Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. Expression of A53T mutant but not wild type a-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release and autophagic cell death. j Neurosci. 21,9549-9560 (2001).
   Google Scholar
• France-Lanord V, Brugg B, Michel PP, Agid Y, Ruberg M. Mitochondrial free radical signal in ceramide-dependent apoptosis: a putative mechanism for neuronal death in Parkinson's disease. Neurochem. 69,1612–1621 (1997).
   PubMed Web of Science ®Google Scholar
• ••Describes the pathology of PD.
   Google Scholar
• Gwinn-Hardy K. Genetics of Parkinsonism. Mow Disord. 17,645–656 (2002).
   PubMedGoogle Scholar
• •Contains a very good explanation about the roles of different reported mutations and their influence in PD pathogenesis.
   Google Scholar
• Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219,979–980 (1983).
   PubMed Web of Science ®Google Scholar
• Gambaro G, Anglani F, D'Angelo A. Association studies of genetic polymorphisms and complex disease. Lancet 355,308–311 (2000).
   PubMed Web of Science ®Google Scholar
• Markopoulou K, Langston JW. Candidate genes and Parkinson's disease: where to next? Neurology53, 1382–1383 (1999).
   PubMedGoogle Scholar
• Abbott RD, Ross GW, White LR etal. Environmental, life-style and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. I Neurol 250 (Suppl. 3), 11130–11139 (2003). iii Baldereschi M, Di Carlo A, Vanni P et al Lifestyle-related risk factors for Parkinson's disease: a population-based study. Acta Neurol Scand. 108,239-244 (2003).
   Google Scholar
• •Importance of environmental risk factors involved in etiology and pathology of complex diseases, with particular reference to PD.
   Google Scholar
• Baldi I, Cantagrel A, Lebailly P et al. Association between Parkinson's disease and exposure to pesticides in southwestern France. Neuroepidemiology22, 305–310 (2003).
   PubMed Web of Science ®Google Scholar
• Hernan MA, Chen H, Schwarzschild MA, Ascherio A. Alcohol consumption and the incidence of Parkinson's disease. Ann. Neurol 54,170–175 (2003).
   PubMed Web of Science ®Google Scholar
• Lucking CB, Abbas N, Dun A et al Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile Parkinsonism. The European Consortium on Genetic Susceptibility in Parkinson's disease and the French Parkinson's disease Genetics Study Group. Lancet352, 1355–1356 (1998).
   Google Scholar
• Nussbaum RL, Polymeropoulos MH. Genetics of Parkinson's disease. Hum. Md. Genet. 6,1687–1691 (1997).
   PubMed Web of Science ®Google Scholar
• Majoor-Krakauer D, Willems PJ, Hofman A. Genetic epidemiology of amyotrophic lateral sclerosis. Clin. Genet. 63,83–101 (2003).
   PubMed Web of Science ®Google Scholar
• Amato AA, Prior TW, Barohn RJ, Snyder P, Papp A, Mendell JR. Kennedy's disease: a clinicopathologic correlation with mutations in the androgen receptor gene. Neurology43,791–794 (1993).
   PubMedGoogle Scholar
• Cacabelos R, Alvarez A, Fenandez-Novoa L, Lombardi VR. A pharmacogenomic approach to Alzheimer's disease. Acta Neurol Scand. Suppl. 176,12–19 (2000).
   Google Scholar
• Cacabelos R. The application of functional genomics to Alzheimer's disease. Pharmacogenomics 4,597–621 (2003).
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Pharmacogenomics for the treatment of dementia. Ann. Med. 34, 357–379 (2002).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Bertilsson L, Bruus H, Wolff A, Roots I, Bauer M. Individualized medicine — implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry 36\(Suppl. 3), S235—S243 (2003).
   Google Scholar
• Teter B, Xu PT, Gilbert JR, Roses AD, Galasko D, Cole GM. Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function. j Neurosci. Res. 68,331-336 (2002).
   Google Scholar
• Arranz MJ, Kerwin RW. Advances in the pharmacogenetic prediction of antipsychotic response. Toalcology192, 33–35 (2003).
   PubMed Web of Science ®Google Scholar
• Pickar D. Pharmacogenomics of psychiatric drug treatment. Psychiatr. Clin. North Am. 26,303–321 (2003).
   PubMedGoogle Scholar
• Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum. Ma. Genet. 11,2517–2530 (2002).
   PubMed Web of Science ®Google Scholar
• Noble ER D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am. j Med. Genet. 116B, 103–125 (2003).
   Google Scholar
• Noble EP The DRD2 gene in psychiatric and neurological disorders and its phenotypes. Pharmacogenomicsl, 309–333 (2000).
   Google Scholar
• Siddiqui A, Kerb R, Weale ME et al. Association of multi-drug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl. I Med. 348,1442-1448 (2003).
   Google Scholar
• Sherrington R, Rogaev El, Liang Y et aL Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754–760 (1995).
   PubMed Web of Science ®Google Scholar
• Levy-Lahad E, Wasco W, Poorkaj P et aL Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269,973–977 (1995).
   PubMed Web of Science ®Google Scholar
• Goate A, Chartier-Harlin MC, Mullan M et aL Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704–706 (1991).
   PubMed Web of Science ®Google Scholar
• Saunders AM, Strittmatter WJ, Schmechel D et al. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467–1472 (1993).
   PubMed Web of Science ®Google Scholar
• Hutton M, Lendon CL, Rizzu P et aL Association of missense and 5 '-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702–705 (1998).
   PubMed Web of Science ®Google Scholar
• D'Souza I, Poorkaj P, Hong M et al. Missense and silent tau gene mutations cause frontotemporal dementia with Parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc. Natl Acad. Sci. USA 96,5598–5603 (1999).
   Google Scholar
• Poorkaj P, Muma NA, Zhukareva V et al. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann. NeuroL 52,511–516 (2002).
   Google Scholar
• Spillantini MG, Crowther RA, Kamphorst W, Heutink P, van Swieten JC. Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau. Am.jPathol. 153,1359–1363 (1998).
   Google Scholar
• Murrell JR, Spillantini MG, Zolo P et al. Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits. NeuropathoL Exp. NeuroL 58,1207–1226 (1999).
   Google Scholar
• Kobayashi T, Ota S, Tanaka K etal. A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology. Ann. NeuroL 53,133–137 (2003).
   Google Scholar
• Rosso SM, van Herpen E, Deelen W et aL A novel tau mutation causes a tauopathy with inclusions similar to those in Pick's disease. Ann. NeuroL 51,373–376 (2002).
   PubMedGoogle Scholar
• Neumann M, Schulz-Schaeffer W, Crowther RA et al. Pick's disease associated with the novel Tau gene mutation K369I. Ann. NeuroL 50,503–513 (2001).
   Google Scholar
• Lippa CF, Zhukareva V, Kawarai T et al. Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation. Ann. NeuroL 48,850–858 (2000).
   Google Scholar
• Sperfeld AD, Collatz MB, Baier H et al. FTDP-17: an early-onset phenotype with Parkinsonism and epileptic seizures caused by a novel mutation. Ann. NeuroL 46, 708–715 (1999).
   Google Scholar
• Iijima M, Tabira T, Poorkaj P et aL A distinct familial presenile dementia with a novel missense mutation in the tau gene. Neuroreport10, 497–501 (1999).
   PubMedGoogle Scholar
• Kowalska A, Hasegawa M, Miyamoto K et al. A novel mutation at position +11 in the intron following exon 10 of the tau gene in FTDP-17. I AppL Genet. 43, 535–543 (2002).
   PubMedGoogle Scholar
• Hayashi S, Toyoshima Y, Hasegawa M et al. Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation. Ann. NeuroL 51,525–530 (2002).
   Google Scholar
• Miyamoto K, Kowalska A, Hasegawa M et al. Familial frontotemporal dementia and Parkinsonism with a novel mutation at an intron 10+11-splice site in the tau gene. Ann. NeuroL 50,117–120 (2001).
   Google Scholar
• Spillantini MG, Yoshida H, Rizzini C et al. A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Ann. NeuroL 48,939–943 (2000).
   Google Scholar
• Yasuda M, Takamatsu J, D'Souza I et aL A novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). Ann. NeuroL 47,422–429 (2000).
   Google Scholar
• Stanford PM, Halliday GM, Brooks WS etal. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. Brain 123\(Pt 5), 880–893 (2000).
   Google Scholar
• van Herpen E, Rosso SM, Serverijnen LA et al. Variable phenotypic expression and extensive tau pathology in two families with the novel tau mutation L315R. Ann. NeuroL 54,573–581 (2003).
   Google Scholar
• Iseki E, Matsumura T, Marui W et al. Familial frontotemporal dementia and Parkinsonism with a novel N2 96H mutation in exon 10 of the tau gene and a widespread tau accumulation in the glial cells. Acta NeuropathoL 102,285–292 (2001).
   PubMedGoogle Scholar
• Rosen DR, Siddique T, Patterson D etal. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59–62 (1993).
   Google Scholar
• Hadano S, Yanagisawa Y, Skaug J et al. Cloning and characterization of three novel genes, ALS2CR1, ALS2CR2 and ALS2CR3, in the juvenile amyotrophic lateral sclerosis (ALS2) critical region at chromosome 2q33-q34: candidate genes for ALS2. Genomics 71,200–213 (2001).
   PubMed Web of Science ®Google Scholar
• Sapp PC, Hosier BA, McKenna-Yasek D et al. Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am. j Hum. Genet. 73, 397–403 (2003).
   PubMed Web of Science ®Google Scholar
• Hand CK, Khoris J, Salachas F et al. A novel locus for familial amyotrophic lateral sclerosis on chromosome 18q. Am. Hum. Genet. 70,251-256 (2002).
   Google Scholar
• Hosier BA, Siddique T, Sapp PC etal. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 284, 1664–1669 (2000).
   Google Scholar
• Wilhelmsen KC, Lynch T, Pavlou E, Higgins M, Nygaard TG. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am. Hum. Genet. 55,1159-1165 (1994).
   Google Scholar
• Hentati A, Ouahchi K, Pericak-Vance MA et al. Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics 2,55–60 (1998).
   PubMed Web of Science ®Google Scholar
• Amato AA, Prior TW, Barohn RJ, Snyder P, Papp A, Mendell JR. Kennedy's disease: a clinicopathologic correlation with mutations in the androgen receptor gene. Neurology 43,791-794 (1993). Affiliations
   Google Scholar